MAA
TVTX icon

Managed Account Advisors’s Travere Therapeutics TVTX Stock Holding History

Managed Account Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$136K Buy
+4,114
New +$113K ﹤0.01% 2556

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Managed Account Advisors's TVTX Position: Q2 2015 in Review

Managed Account Advisors opened a new position in Travere Therapeutics (TVTX) in Q2 2015: 4,114 shares worth $136K. The stake represents ﹤0.01% of the portfolio and ranks #2556 among its holdings.

126 funds tracked by Wall St. Rank hold TVTX as of Q2 2015.

  • Managed Account Advisors held 4,114 shares of Travere Therapeutics worth $136K as of Q2 2015.
  • Travere Therapeutics was a new Managed Account Advisors position in Q2 2015.
  • Travere Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2556 holding.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.